ProShare Advisors LLC Has $3.18 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

ProShare Advisors LLC lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 45.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 30,137 shares of the medical equipment provider's stock after selling 24,819 shares during the quarter. ProShare Advisors LLC's holdings in Zimmer Biomet were worth $3,183,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Roman Butler Fullerton & Co. acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $473,000. KLCM Advisors Inc. bought a new position in Zimmer Biomet in the fourth quarter valued at approximately $7,825,000. Van ECK Associates Corp boosted its holdings in shares of Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after buying an additional 218,688 shares during the period. Lmcg Investments LLC increased its position in shares of Zimmer Biomet by 20.4% during the fourth quarter. Lmcg Investments LLC now owns 55,949 shares of the medical equipment provider's stock worth $5,910,000 after acquiring an additional 9,484 shares in the last quarter. Finally, MFG Wealth Management Inc. acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $1,506,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Down 1.2%

Shares of Zimmer Biomet stock opened at $95.80 on Tuesday. The business has a fifty day simple moving average of $103.24 and a two-hundred day simple moving average of $105.76. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.92 and a 1 year high of $120.13. The company has a market capitalization of $18.95 billion, a price-to-earnings ratio of 21.53, a P/E/G ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The business had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter last year, the firm posted $1.94 EPS. The company's quarterly revenue was up 1.1% on a year-over-year basis. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.00%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet's dividend payout ratio is 21.24%.

Analysts Set New Price Targets

A number of research firms have issued reports on ZBH. The Goldman Sachs Group lowered their target price on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. JPMorgan Chase & Co. reduced their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. JMP Securities lowered their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Raymond James cut their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $113.45.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.39% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.